Skip to main content
. 2024 May 8;2:1–30. doi: 10.1162/imag_a_00171

Fig. 3.

Fig. 3.

Pathological assessment for each regional pathology derived from histology as per the protocol discussed in Section 2.3. The columns are severity ratings (left to right): 0-3. The shown pathologies are: amyloid- β plaques (NAB228 antibody), p-tau pathology (PHF-1 antibody), α-synuclein (Syn303 antibody), TDP-43 inclusions (pS409/410 antibody), and neuron loss (Hematoxylin and Eosin staining) in different cortical and medial temporal lobe regions included in the current work.